Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Clinical benefit of ALK tyrosine kinase inhibitors (ALK‐TKIs) in ALK‐rearranged lung cancer has been limited by the inevitable development of acquired resistance, and bypass‐molecular resistance mechanisms remain poorly understood. We investigated a novel therapeutic target through screening FDA‐app...

Full description

Saved in:
Bibliographic Details
Published in:EMBO Mol Med
Main Authors: Yun, Mi Ran, Choi, Hun Mi, Lee, You Won, Joo, Hyeong Seok, Park, Chae Won, Choi, Jae Woo, Kim, Dong Hwi, Kang, Han Na, Pyo, Kyoung‐Ho, Shin, Eun Joo, Shim, Hyo Sup, Soo, Ross A, Yang, James Chih‐Hsin, Lee, Sung Sook, Chang, Hyun, Kim, Min Hwan, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2019
Subjects:
Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6895608/
https://ncbi.nlm.nih.gov/pubmed/31633304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/emmm.201910581
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items